Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 2 Pancreatic Neoplasms 1 Neoplasms, Glandular and Epithelial 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Neoplasms 1 Melanoma 1 Locally Advanced Rectal Adenocarcinoma 1 Locally Advanced Cervical Carcinoma 1 Liver Neoplasms 1 Liver Diseases 1 Head and Neck Neoplasms 1 Gastric Cancer With Liver Metastases 1 Esophageal Neoplasms 1 Digestive System Neoplasms 1 Digestive System Diseases 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Breast Neoplasms 1 Adenocarcinoma 1

Interventions

Nivolumab 21 pembrolizumab 19 Ipilimumab 14 Specimen Handling 12 Magnetic Resonance Spectroscopy 7 Opdualag 6 CTLA-4 Antigen 6 relatlimab 5 binimetinib 5 trametinib 4 Paclitaxel 4 dabrafenib 3 Taxes 3 Standard of Care 3 Pemetrexed 3 Introns 3 Interferon alpha-2 3 Gemcitabine 3 Carboplatin 3 Blood Specimen Collection 3 ulixertinib 2 sargramostim 2 lifileucel 2 lenvatinib 2 fludarabine phosphate 2 fludarabine 2 encorafenib 2 capivasertib 2 cabozantinib 2 atezolizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × Immunotherapy × 30 days × Clear all

NCT02645149 2026-05-29

Match Mel

Melanoma Institute Australia

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡